12:44 PM EDT, 09/11/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Wednesday it has priced a best-efforts offering of about 12.3 million shares at $0.69 per share for gross proceeds of about $8.5 million.

The clinical-stage biotechnology company said it expects to close the offering Thursday, with ThinkEquity as placement agent. Investors have the option to buy pre-funded warrant instead of shares.

BriaCell said the use of proceeds include for working capital and general corporate purposes.

The stock was up more than 16% in recent trading.

Price: 0.72, Change: +0.10, Percent Change: +16.41